Correction to “Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2024-11-18 DOI:10.1111/dom.16083
{"title":"Correction to “Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”","authors":"","doi":"10.1111/dom.16083","DOIUrl":null,"url":null,"abstract":"<p>\n <span>Kelly, MS</span>, <span>Scopelliti, EM</span>, <span>Goodson, KE</span>, <span>Lo, CMA</span>, <span>Nguyen, HX</span>, <span>Simon, B</span>. <span>Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus</span>. <i>Diabetes Obes Metab.</i> <span>2024</span>; <span>26</span>(<span>12</span>): <span>5661</span>–<span>5668</span>. doi:10.1111/dom.15934\n </p><p>In the first paragraph of the introduction paragraph, reference #3 is cited as the “SUSTAIN trial”, which is incorrect. This should have read, “SURMOUNT-1 trial” and does reference the correct trial.</p><p>We apologize for this error.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 2","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16083","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16083","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Kelly, MS, Scopelliti, EM, Goodson, KE, Lo, CMA, Nguyen, HX, Simon, B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024; 26(12): 56615668. doi:10.1111/dom.15934

In the first paragraph of the introduction paragraph, reference #3 is cited as the “SUSTAIN trial”, which is incorrect. This should have read, “SURMOUNT-1 trial” and does reference the correct trial.

We apologize for this error.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对 "替扎帕肽对 2 型糖尿病患者疗效的真实世界评估 "的更正。
Kelly, MS, Scopelliti, EM, Goodson, KE, Lo, CMA, Nguyen, HX, Simon, B.替西帕肽治疗2型糖尿病的临床疗效评价。糖尿病杂志。2024;26日(12):5661 - 5668。doi: 10.1111 / dom.15934在引言段的第一段,参考文献#3被引用为“SUSTAIN试验”,这是不正确的。这应该读作“SURMOUNT-1试验”,并且确实引用了正确的试验。我们为这个错误道歉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study. Residual Gastric Content in Hospitalised GLP-1RA Users: Considerations for Interpretation. Counting days: Cardiovascular and kidney event postponement with glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes. Sex-specific associations of body mass index and waist circumference loss with the risk of atrial fibrillation. Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1